Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

1.47
-0.0500-3.29%
Post-market: 1.500.0323+2.20%18:25 EST
Volume:2.26M
Turnover:3.34M
Market Cap:614.46M
PE:-7.77
High:1.51
Open:1.50
Low:1.44
Close:1.52
52wk High:1.83
52wk Low:0.2836
Shares:418.00M
Float Shares:239.00M
Volume Ratio:1.27
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1891
EPS(LYR):-0.6262
ROE:-45.92%
ROA:-12.94%
PB:5.11
PE(LYR):-2.35

Loading ...

Lexicon Pharmaceuticals Director Raymond Debbane Acquires Common Shares

Reuters
·
Feb 19

Lexicon Pharmaceuticals Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Feb 18

Lexicon Pharmaceuticals Files Initial Beneficial Ownership Statement for Avicenna Life Sci Master Fund

Reuters
·
Feb 13

Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing

TIPRANKS
·
Feb 03

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology

Reuters
·
Jan 30

BRIEF-Lexicon Announces Pricing Of Approximately $94.6 Million Public Offering At $1.30 Per Share

Reuters
·
Jan 30

Lexicon Pharmaceuticals Inc - Shares Offered at $1.30 per Share

THOMSON REUTERS
·
Jan 30

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THOMSON REUTERS
·
Jan 30

BUZZ-Lexicon Pharma slides after stock offering unveil

Reuters
·
Jan 30

Lexicon announces common stock offering, no amount given

TIPRANKS
·
Jan 30

Lexicon Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jan 30

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

GlobeNewswire
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

Reuters
·
Jan 21

BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous

Reuters
·
Jan 21

BUZZ-Lexicon rises as FDA clears late‑stage test of diabetic nerve‑pain drug

Reuters
·
Jan 21

Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Neuropathic Pain

Reuters
·
Jan 21

Lexicon Pharmaceuticals Inc - FDA Raised No Objections to Advancement of Pilavapadin Into Phase 3 Development

THOMSON REUTERS
·
Jan 21

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

THOMSON REUTERS
·
Jan 21

Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target

TIPRANKS
·
Jan 21

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)

TIPRANKS
·
Jan 16